$AVPT

AvePoint Announces Second Quarter 2026 Financial Results

AvePoint, Inc. (AVPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 AvePoint Announces Second Quarter 2026 Financial Results Second quarter SaaS revenue of $98.5 million, representing 27% year-over-year growth, 26% on a constant currency basis Second quarter Total revenue of $124.5 million, representing 22% year-over-year growth, 21%

Original reporting
Published Aug 6, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AVPT
Bullish
medium confidence
Mentioned
$AVPT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AVPTBullishHigh
01

Why it matters

The key tradable items are the raised full-year guidance and the specific Q3 and FY 2026 revenue and non-GAAP operating income ranges, which can re-anchor valuation expectations for the next quarter.

02

Market read

A guidance raise with detailed Q3 and FY ranges is a direct catalyst for earnings-model updates and near-term positioning.

03

What to watch

Investors may discount the guidance raise if FX volatility is expected to worsen, since the company says the FX headwind more than offset the ARR and operating outperformance.

Relevance 7/10Novelty 9/10Timing: after-hours guidance and Q2 print, conference call scheduled 4:30pm ET today

Background

This is an SEC 8-K with Exhibit 99.1 press release covering AvePoint’s Q2 2026 financial results, KPIs, and updated guidance.

Company-level read

Ticker impact

$AVPTBullishMedium confidence
Context

AvePoint reported Q2 2026 results and raised full-year ARR, revenue, and non-GAAP operating income guidance, plus issued Q3 revenue and non-GAAP op income ranges.

Expected impact

Moderately positive reaction risk, with follow-through dependent on whether investors focus on ARR growth quality (retention) versus FX and margin normalization.

Evidence & confidence

The filing includes specific Q3 and FY 2026 guidance ranges and states full-year guidance is being raised, which is actionable for positioning around the next earnings window.

Market effects

Reinforces demand narrative for AI governance, security, and backup controls, potentially supportive for enterprise trust-layer SaaS peers.

Limited direct regional impact; company also references SGX listing but guidance is US-focused.

FX headwind disclosure highlights currency sensitivity for global SaaS revenue and ARR reporting.

Counterpoint

Non-GAAP operating margin declined versus prior year, suggesting profitability may be pressured even as growth accelerates.

Key entities

  • AvePoint, Inc.

    Nasdaq-listed AI trust-layer SaaS provider reporting Q2 2026 results and raising full-year guidance.

  • Dr. Tianyi Jiang (TJ)

    CEO and co-founder quoted on demand for trusted AI and platform momentum.

Related articles

$AVPTMedAI 9/10

AvePoint (AVPT) Q2 2026 Earnings Call Transcript

AvePoint (AVPT) reported Q2 2026 revenue of $124.5M, up 22% YoY, with SaaS revenue $98.5M (79% of total). Total ARR was $465.1M (+27%), net new ARR $29.9M, and GAAP operating margin 8.2%. Full-year guidance: ARR $522.1M-$528.1M and revenue $508.5M-$512.5M. The company also spent $50M on share repurchases in Q2.

$AVPTHighAI 9/10

AvePoint lifts annual recurring revenue guidance after Q2

AvePoint reported Q2 2026 revenue of $124.5M and raised full-year annual recurring revenue guidance. SaaS revenue was $98.5M, up 27% y/y, and ARR ended at $465.1M, up 27%. Q3 revenue is forecast at $128.2M to $130.2M, and full-year ARR at $522.1M to $528.1M. The company cited demand for AI governance.

$LEVIHighAI 8/10

Levi's CEO admits the company missed the biggest jeans trend of the year

Levi Strauss & Co. (LEVI) CEO Michelle Gass admitted the company missed the U.S. shift to low-rise jeans during the back-to-school season, impacting its direct-to-consumer sales. Despite a 4% revenue increase to $1.6 billion in Q3, shares fell nearly 5%. Levi's has since refocused marketing on low-rise styles and expects full-year revenue growth of about 6%.

$REGNMed

Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month

Regeneron (REGN) reported positive long-term results for its rare disease drug Pasatru, showing no new abnormal bone growth in an extended Phase 3 trial. The trial enrolled 63 adults, with zero new lesions in the Pasatru group compared to nine in the placebo group. REGN shares rose 2.8%, their best day in over a month. BofA raised its price target to $908, implying 19% upside. The company plans a new study for children and adolescents later this year.